Odyssean LLC Has $1.74 Million Stock Holdings in TG Therapeutics, Inc. $TGTX

Odyssean LLC raised its stake in TG Therapeutics, Inc. (NASDAQ:TGTX) by 107.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,652 shares of the biopharmaceutical company’s stock after buying an additional 16,398 shares during the period. Odyssean LLC’s holdings in TG Therapeutics were worth $1,739,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Danske Bank A S bought a new position in shares of TG Therapeutics in the 3rd quarter valued at $25,000. EverSource Wealth Advisors LLC grew its position in TG Therapeutics by 51.9% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 365 shares during the last quarter. Hantz Financial Services Inc. increased its holdings in TG Therapeutics by 82.7% in the 4th quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 560 shares in the last quarter. Truvestments Capital LLC raised its position in TG Therapeutics by 172.4% in the fourth quarter. Truvestments Capital LLC now owns 1,621 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 1,026 shares during the last quarter. Finally, Kemnay Advisory Services Inc. bought a new position in TG Therapeutics in the fourth quarter valued at about $52,000. Institutional investors own 58.58% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on TGTX. JPMorgan Chase & Co. upped their price objective on TG Therapeutics from $65.00 to $72.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. B. Riley Financial boosted their target price on shares of TG Therapeutics from $55.00 to $86.00 and gave the stock a “buy” rating in a report on Monday, July 27th. HC Wainwright reaffirmed a “buy” rating and set a $78.00 price target on shares of TG Therapeutics in a research note on Tuesday. Jefferies Financial Group reiterated a “buy” rating and set a $83.00 price target on shares of TG Therapeutics in a report on Monday, June 22nd. Finally, Bank of America boosted their price objective on shares of TG Therapeutics from $17.00 to $20.00 and gave the stock an “underperform” rating in a research note on Tuesday, July 7th. Five research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $63.00.

TG Therapeutics Stock Performance

Shares of TGTX stock opened at $55.99 on Friday. The business’s 50 day simple moving average is $53.54 and its 200 day simple moving average is $42.77. TG Therapeutics, Inc. has a one year low of $26.76 and a one year high of $59.30. The stock has a market capitalization of $8.57 billion, a PE ratio of 20.43, a PEG ratio of 2.43 and a beta of 1.67. The company has a debt-to-equity ratio of 1.23, a current ratio of 4.27 and a quick ratio of 3.72.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by ($0.26). The firm had revenue of $240.34 million for the quarter, compared to the consensus estimate of $229.77 million. TG Therapeutics had a return on equity of 73.49% and a net margin of 55.22%.The firm’s revenue for the quarter was up 70.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.17 EPS. As a group, research analysts forecast that TG Therapeutics, Inc. will post 0.92 earnings per share for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.